Inclusion criteria : 
   1.  Patients with locally advanced or metastatic renal cell carcinoma
   2.  Whose first - line treatment included at least one anti - angiogenic agent ( tyrosine kinase inhibitor or monoclonal antibodies ) and / or an mTOR inhibitor;
   3.  Whatever was the overall ECOG - PS score ( Eastern Cooperative Oncology Group Performance Status ) at treatment initiation time
   4.  With first - line treatment carried out between  2007 and June  2016. 
Exclusion criteria : 
   1.  Patient previously treated with only one cytokine ( Interferon Î± 2 a , high - dose interleukin -  2 ) 
   2.  Refusal of processing of personal data